GGrantIndex
← Search

Membranes, Organelles, and Metabolism (MOM) Research Program

$54,294P30FY2022CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

ABSTRACT – MEMBRANES, ORGANELLES, AND METABOLISM Membranes, Organelles, and Metabolism (MOM) is a new program that was created during the reorganization of the Basic Science Division in the Lurie Cancer Center (LCC). The program is founded on the emerging concept that signaling and metabolic pathways rely on association with a physically interconnected network of cell membranes and membrane-bound organelles, which are exploited by developing tumors to promote malignant transformation and progression. Integration of the classic view of cellular signaling as a series of biochemical reactions with this current perspective provides a clearly articulated focus for an outstanding group of basic science investigators studying mitochondrial biogenesis and function, metabolism, signal transduction and host- pathogen interactions. The broad objectives of MOM are to elucidate how cellular membranes and organelles drive cell response and effector cascades, to determine how tumors and tumor-causing pathogens exploit these pathways, and to identify pathway components as therapeutics targets. These objectives are pursued in three specific aims: (1) Understand how cells utilize metabolic pathways to dictate cell proliferation, metabolic adaptation, and gene expression thereby modulating tumor growth; (2) Define the molecular mechanisms by which pathogens disrupt and/or utilize host pathways to stimulate tumorigenesis; (3) Determine how signal transduction pathways initiated from plasma membrane and/or organelles are integrated in cancer cells to promote tumorigenesis. The MOM program leader is Navdeep S. Chandel Ph.D., Professor in the Department of Medicine and the Department Cell and Molecular Biology. He is an expert in cancer metabolism, mitochondrial biology, and oxidative stress. The co-leader is Curt Horvath, Ph.D., a Professor in the Department of Molecular Biosciences, whose expertise is in mechanisms of cytokine signal transduction and gene regulation in normal and malignant cells. Drs. Chandel and Horvath lead an interdepartmental cohort of investigators comprising 36 faculty from 10 departments and 3 schools. Between 2013 and 2017 there were 405 cancer-relevant publications from the program, 71 (18%) of which represent intra-programmatic collaborations and 157 (39%) represent inter- programmatic collaborations. Work in the MOM program is supported by cancer-relevant peer-reviewed funding of $12,161,291 (direct) with $2,187,789 (direct) from NCI and $9,973,502 (direct) from other peer-reviewed sources. The MOM program provides its members with the research support, tools, and scientific networking opportunities to achieve an understanding of how interference with membrane networks and metabolism contributes to cell transformation and tumor progression. Through MOM-sponsored monthly membership meetings, workshops, symposia, and seminar series, the program fosters collaboration between program members and their clinical/translational partners, and links investigators with new opportunities to advance their research within the LCC.

View original record on NIH RePORTER →